Varaico: Literature-Extracted Genetic Variants

Gene:BTK
Variant:p.T474S
Back to variants list

BTK

NM_000061.3:p.T474S

Associated Papers

Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.

Brown JR et al.

Blood, 2026

41055698 (PubMed )
Supplement: BLOOD_BLD-2024-027009-mmc4.xlsx › Sheet_1

Computational insights into mutation-induced binding changes in Bruton's Tyrosine Kinase with non-covalent inhibitors.

Mallen JJ et al.

Journal of Biomolecular Structure & Dynamics, 2025

A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.

Wiśniewski K et al.

International Journal of Molecular Sciences, 2024

BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib.

Jackson RA et al.

Blood Advances, 2023

37257190 (PubMed )
Supplement: BLOODA_ADV-2022-009366-mmc1.pdf

Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models.

Lim YS et al.

Blood Advances, 2023

36269842 (PubMed )
Supplement: BLOODA_ADV-2022-008121-mmc1.pdf

Battling BTK mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations in Waldenström macroglobulinemia therapy: structural mechanistic insights on the role of fenebrutinib.

Elamin G et al.

Journal of Molecular Modeling, 2022

BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.

Estupiñán HY et al.

Leukemia, 2021

KinaseMD: kinase mutations and drug response database.

Hu R et al.

Nucleic Acids Research, 2021

33137204 (PubMed )
Supplement: gkaa945_supplemental_files.zip › Supplementary_Table_S3.xlsx › Sheet1

Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.

Roskoski R

Pharmacological Research, 2016

Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.

Johnson AR et al.

Acs Chemical Biology, 2016

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.

Maddocks KJ et al.

Jama Oncology, 2015

Select a paper to view details
UCSC Genome Browser·Imprint·Privacy·Terms·Feedback·Email Updates·

Regarding the variants extracted from papers and shown text snippets from research papers, the following holds: "Some rights reserved. This work permits non-commercial use, distribution and reproduction in any medium, provided the original author and source are credited."